Life-threatening adverse drug reactions causing - neutropaenia

Description

Drug-induced neutropenia arises through either predictable, dose-dependent bone marrow suppression (most cytotoxic chemotherapy) or unpredictable, idiosyncratic immune-mediated destruction (certain non-chemotherapy drugs, e.g. clozapine, some antithyroid drugs, some antibiotics) - the distinction matters since idiosyncratic neutropenia can occur even at standard therapeutic doses without warning

A significant cause of drug-related morbidity given the infection risk it creates, with certain agents (clozapine, carbimazole/propylthiouracil) carrying a well-recognised, specifically monitored idiosyncratic neutropenia/agranulocytosis risk

Predictable marrow-suppressive drugs cause dose-dependent neutrophil precursor toxicity, with neutrophil count falling in a relatively predictable timeframe after dosing; idiosyncratic drug-induced neutropenia reflects an immune-mediated or direct toxic mechanism against mature neutrophils or precursors that is not straightforwardly dose-related, explaining why it can occur unpredictably, sometimes after a variable delay following drug exposure

Mandatory regular full blood count monitoring for drugs with recognised idiosyncratic agranulocytosis risk (clozapine being the paradigm example, with a structured, non-negotiable monitoring schedule) - allows detection before clinical infection develops
Any unexplained fever or infection symptom in a patient on a neutropenia-risk drug should prompt an urgent full blood count

Immediate causative drug cessation on confirmed significant neutropenia, particularly for idiosyncratic reactions where re-challenge carries recurrence risk
Febrile neutropenia (fever with significant neutropenia) is a medical emergency requiring urgent empirical broad-spectrum antibiotics regardless of the causative drug, per standard febrile neutropenia protocols
Growth factor (G-CSF) support may be used in selected cases to accelerate neutrophil recovery

Clozapine-associated agranulocytosis (mandatory monitoring, the classic teaching example), antithyroid drug (carbimazole/propylthiouracil)-associated agranulocytosis, chemotherapy-associated predictable neutropenia and febrile neutropenia risk, drug re-challenge risk after idiosyncratic neutropenia

Idiosyncratic drug-induced agranulocytosis (as with clozapine or antithyroid drugs) can occur unpredictably and is not reliably dose-related, unlike the predictable, dose-dependent marrow suppression seen with cytotoxic chemotherapy - this is why mandatory structured blood count monitoring, not just clinical vigilance for symptoms, is required for drugs with this specific risk profile

6 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.